Modulus Therapeutics, spun out of the Allen Institute for AI, raises $3.5M to engineer enhanced NK cell therapies

Modulus Therapeutics, a Seattle cell-therapy startup spun out of the Allen Institute for AI, raised $3.5 million in seed funding to use lab research and machine learning to engineer enhanced natural killer (NK) cells for anti-tumor therapies. Founders Max Darnell and Bryce Daines aim to develop a discovery platform to generate NK cell product candidates for larger cellular therapy companies.